| Literature DB >> 35631173 |
Anna-Lena Mueller1, Aranka Brockmueller1, Ajaikumar B Kunnumakkara2, Mehdi Shakibaei1.
Abstract
Tendinitis (tendinopathy) is a pro-inflammatory and painful tendon disease commonly linked with mechanical overuse and associated injuries, drug abuse, and lifestyle factors (including poor diet and physical inactivity) that causes significant healthcare expenditures due to its high incidence. Nuclear factor kappa B (NF-κB) is one of the major pro-inflammatory transcription factors, along with other inflammation signaling pathways, triggered by a variety of stimuli, including cytokines, endotoxins, physical and chemical stressors, hypoxia, and other pro-inflammatory factors. Their activation is known to regulate the expression of a multitude of genes involved in inflammation, degradation, and cell death. The pathogenesis of tendinitis is still poorly understood, whereas efficient and sustainable treatment is missing. Targeting drug suppression of the key inflammatory regulators represents an effective strategy for tendinitis therapy, but requires a comprehensive understanding of their principles of action. Conventional monotherapies are often ineffective and associated with severe side effects in patients. Therefore, agents that modulate multiple cellular targets represent therapeutic treatment potential. Plant-derived nutraceuticals have been shown to act as multi-targeting agents against tendinitis via various anti-oxidant and anti-inflammatory mechanisms, whereat they were able to specifically modulate numerous signaling pathways, including NF-κB, p38/MAPK, JNK/STAT3, and PI3K/Akt, thus down-regulating inflammatory processes. This review discusses the utility of herbal nutraceuticals that have demonstrated safety and tolerability as anti-inflammatory agents for the prevention and treatment of tendinitis through the suppression of catabolic signaling pathways. Limitations associated with the use of nutraceuticals are also described.Entities:
Keywords: inflammation; nutraceuticals; polyphenols; tendinitis; tendinopathy; tendon; tissue engineering
Mesh:
Substances:
Year: 2022 PMID: 35631173 PMCID: PMC9143056 DOI: 10.3390/nu14102030
Source DB: PubMed Journal: Nutrients ISSN: 2072-6643 Impact factor: 6.706
Figure 1Inflammation in the context of different chronic disorders.
Figure 2Molecular backgrounds of NF-κB, STAT3, p38/MAPK signaling linking inflammation, and degradation. Under physiological conditions, NF-κB is located as a heterodimeric complex of p50 and p65 bound to its inhibitor IκBα in the cytoplasm. The upstream IKK complex can activate IκBα by its phosphorylation and ubiquitin-dependent degradation, leading to NF-κB release that is then activated (p65- NF-κB) and translocates into the nucleus to activate the transcription of target genes, including cytokines and pro-inflammatory enzymes. The activation of the p38/MAPK signaling pathway by upstream MAPKK is promoted by external stimuli linked to stress and inflammation, binding to various receptors. Activated p38 in turn results in the transcription of several pro-inflammatory genes, such as COX-2, iNOS, MMPs, or RANKL, which are strongly involved in tissue remodeling. Another major signaling pathway involved in inflammation, the JAK/STAT3 pathway, is activated by IL-6, consequently inducing STAT3 phosphorylation and activation, which then translocates to the nucleus, where it regulates the expression of many genes linked to apoptosis, inflammation, and tissue degradation, such as Bcl-XL, COX-2, and various cytokines. Abbreviations: COX-2; cyclooxygenase-2, IκBα; NF-κB inhibitor alpha, IKK; IκB kinase, IL-1 β; Interleukin 1 beta, iNOS; inducible nitric oxide synthase, JAK; Janus kinase, MAPKK; MAPK kinase, MAPKKK; MAPKK kinase, MMPs; matrix metalloproteinases, PARP; Poly(ADP-Ribose)-Polymerase, RANKL; receptor activator of NF-κB ligand, STAT3; signal transducer and activator of transcription 3, TNF- α; tumor necrosis factor alpha, TNF- β; tumor necrosis factor beta.
Figure 3Distinct plant-based nutraceuticals and their regulatory mechanisms for fighting tendinitis. Various polyphenols have been demonstrated to modulate inflammatory mechanisms by downregulating major pro-inflammatory players (e.g., NF-κB, caspase-3, MMPs, PI3K) and upregulating expression of genes required for tendon vitality and proliferation (e.g., Scleraxis, tenomodulin, collagen, Sirt-1), and thereby help to fight tendinitis. Abbreviations: AGE; advanced glycation end-products, Akt; serine/threonine kinase B, AP; alkaline phosphatase, Bax; Bcl-2-associated X protein, Bcl-2; B-cell lymphoma 2, COMP; cartilage oligomeric matrix protein, COX-2; cyclooxygenase-2, ECM; extracellular matrix, ERK; extracellular signal-regulated kinase, GAGs; glycosaminoglycans, GPX; glutathione peroxidase, HoPro; hydroxyproline, ICAM-1; Intercellular Adhesion Molecule 1, IL-1 β; Interleukin 1 beta, JNK; c-Jun N-terminal kinase, MAD; mitotic arrest deficient, MAPK; mitogen-activated protein kinase, MMPs; matrix metalloproteinases, NF-κB; nuclear factor kappa B, PAF; platelet-activating factor, Pcna; proliferating cell nuclear antigen, PGE2; prostaglandin E2, PI3K; phosphoinositide-3-kinase, ROS; reactive oxygen species, SAPK; stress-activated phospho-kinases, Sirt-1; Sirtuin-1, SOD; superoxide dismutase, STAT3; signal transducer and activator of transcription 3, Timp1;tissue inhibitor of metalloproteinase 1, TNF- α; tumor necrosis factor alpha, TNF- β; tumor necrosis factor beta, VEGF; vascular endothelial growth factor.
Tendon-supporting effects of phytopharmaceuticals.
|
|
|
|
|
|
|
|
|---|---|---|---|---|---|---|
|
|
| in vitro, | IL-1β | Avocado/soybean unsaponifiables significantly inhibited inflammation response, such as combination therapy with glucosamine and chondroitin sulfate. | 8.3 μg/mL of ASU | [ |
|
|
| in vivo, | - | Boswellia acid (as Casperome®) showed pain reduction on a visual analogical scale when Casperome® was administered in addition to physical therapy in patients with Achilles tendinitis. | 250 mg of Casperome® for 15 and 30 days | [ |
| in vivo, | - | Boswellia acid (as Casperome®) supplementation accompanied by standard therapy reduced pain and inflammation in knee joints and tendon of rugby players. | 500 mg of Casperome® for 5 days, then 250 mg for 23 days | [ | ||
| in vivo, | - | 2 daily sachets Tendisulfur® for 15 days, then 1 daily sachet for 45 days | [ | |||
| in vivo, | - | 2 tablets twice a day for 1 month | [ | |||
| in vivo, | - | 2 daily tablets of Tendisulfur® Forte for 1 month, then once a day for a month | [ | |||
|
| in vivo, | MDA | Pineapple flesh extract stimulated tenoblast proliferation and thus tendon healing after Achilles tendon injury. | 30 mg/kg of pineapple flesh axtract for 14 days | [ | |
| in vivo, | ROS | Pineapple extract bromelain shifted the thromboxane–prostacyclin ratio towards prostacyclin and increased the tenocyte population after Achilles tendon injury. | 7 mg/kg of bromelain for 14 days | [ | ||
| in vivo, | - | Pineapple extract bromelain (as dietary supplement Tenosan with arginine, collagen, vitamin C, methyl-sulfonyl-methane, VinitroxTM) boosted the efficacy of extracorporeal shock wave therapy, resulting in better functional and clinical outcome, compared to placebo treatment. | 2 daily drug sachets containing 50 mg of bromelain for 60 days | [ | ||
| in vivo, | - | Pineapple extract bromelain (as dietary supplement Tenosan with arginine L-alpha-ketoglutarate, methyl-sulfonyl-methane and hydrolysed collagen I) reduced pain and improved repair integrity of rotator cuff repair. | 2 daily drug sachets containing 50 mg of bromelain for 3 months | [ | ||
| in vivo, | - | Pineapple extract bromelain (with methyl-sulfonyl-methane, hydrolysed collagen I and II, L-arginine, L-lysin, vitamin C, chondroitin sulfate, glucosamine, | 2 daily tablets of Tendisulfur® Forte for 1 month, then once a day for an additional month | [ | ||
|
|
| in vitro, | NF-κB | Calebin A suppressed inflammation and exhibited potential as preventive and therapeutic treatment of tendinitis by suppressing down-regulation of tenomodulin and collagen I. | 1–10 µM of calebin A | [ |
| in vitro, | NF-κB | Curcumin inhibited inflammation and apoptosis and showed potential for treatment of tendon inflammation. | 5 µM of curcumin | [ | ||
| in vivo, | ROS | Curcumin reduced oxidative stress by inhibiting lipid peroxidation and prevented glycation and crosslinking of advanced glycated collagen in tail tendon and skin. | 200 mg/kg of curcumin for 8 weeks | [ | ||
| in vivo, | MDA | Curcumin improved the healing quality of tendon ruptures by promoting well-organized collagen filaments and biomechanical traits. | 100 mg/kg of curcumin for 14 days | [ | ||
| in vivo, | adhesion of inflammatory products | Curcumin (as loaded nanoparticle) promoted the healing process of Achilles tendon rupture. | 1 injection containing 0.44 mg of curcumin/kg | [ | ||
| in vivo, | - | Curcumin showed biomechanical and histological healing (collagen I and III) promotion after surgically treated Achilles tendon ruptures. | 200 mg/kg of curcumin for 28 days | [ | ||
| in vivo, | AP | Curcumin prevented tendon calcification and improved tendon regeneration by tendon stem/progenitor cells. | 3 μg of curcumin every 3 days for up to 4 weeks | [ | ||
| in vivo, | ROS | Curcumin showed anti-oxidative and anti-inflammatory properties as part of Cur&Mg-QCS/PF hydrogel application. | 1 injection with 50 µL of hydrogel | [ | ||
| in vivo, | AGE | Curcumin’s metabolite tetrahydrocurcumin reduced accumulation and crosslinking of advanced glycated collagen. | 80 mg/kg of tetrahydrocurcumin for 45 days | [ | ||
| in vivo, | - | 2 tablets twice a day for 1 month | [ | |||
| in vivo, | - | 2 daily tablets of Tendisulfur® Forte for 1 month, then once a day for an additional month | [ | |||
| in vivo, | - | 2 daily sachets of Tendisulfur® for 15 days and 1 daily sachet for the next 45 days | [ | |||
|
|
| in vitro, | IL-1β | Green tea’s epigallocatechin gallate targeted extracellular matrix breakdown. | 2.5–25 µM of epigallocatechin gallate | [ |
| in vivo, | AGE | Green tea extract reduced collagen glycation and crosslinking in the tail tendon. | 300 mg/kg of green tea extract for 4 weeks | [ | ||
| in vivo, | MMPs | Green tea promoted the synthesis of ECM components and glycosaminoglycans, and thus the recovery process after Achilles tendinitis in combination with a glycin diet. | 700 mg/kg of green tea extract for 21 days | [ | ||
| in vivo, | IL-1β | Green tea modulated inflammatory action and promoted synthesis of recovery elements after Achilles tendinitis, in combination with a glycin diet. | 700 mg/kg of green tea extract for 7 days | [ | ||
| in vivo, | ROS | Green tea extract slowed collagen aging by inhibiting crosslinking. | 21.2 mL (young mice) and 27.2 mL (adult mice) of green tea extract for 14 days | [ | ||
|
|
| in vivo, | - | 2 capsules containing 250 mg of echinacea extract for 40 days, then 1 capsule for 80 days | [ | |
|
|
| in vitro, | ROS | Flavonoid anthocyanin acted as an anti-apoptotic and showed the therapeutic potential of rotator cuff tendon. | 10–200 µg/mL of anthocyanins | [ |
| in vitro, | caspase-3 | Flavonoid eriocitrin inhibited apoptosis and scar formation (biglycan, fibronectin, COMP) and improved woundhealing by stimulating proliferation and migration of tendon stem cells. | 25–75 of µM eriocitrin | [ | ||
| in vivo, | - | Flavone genistein protected ovariectomy-induced collagen reduction in Achilles tendon. | 300 mg/kgof genistein for 6 weeks | [ | ||
| in vivo, | Pcna | Flavone genistein enhanced tendon function at an estrogen-deficit through the modulation of tenomodulin. | 6 mg/kg of genistein for 6 weeks | [ | ||
| in vivo, | AP | Flavonoid icariin supported healing and angiogenesis after rotator cuff reconstruction through promoting collagen I/II. | 0.125 mg/g of icariin for 2 and 4 weeks | [ | ||
| in vivo, | ROS | Flavonoid quercetin prevented the adhesion of tendon tissue. | 50–100 mg/kg for 4 weeks | [ | ||
| in vivo, | MMPs | Flavonoid quercetin prevented collagenase-induced tendon damage at Achilles tendinopathy. | 25–50 mg/kg for 7 days | [ | ||
| in vivo, | - | Flavonoid quercetin, kaempferol, and isorhamnetin ( | 1 injection with 0.1 mg of | [ | ||
|
|
| in vitro, | NF-κB | Resveratrol regulated tenocytes homeostatic and inhibited inflammation of cascades and apoptosis. | 5 µM of resveratrol | [ |
| in vitro, | Sirt-1 | Resveratrol averted dexamethasone-induced senescence despite glucocorticoid treatment. | 30 µM of resveratrol | [ | ||
| in vitro, | NF-κB | Resveratrol inhibited inflammation cascades; prevented apoptosis; and promoted collagen I, collagen III, and tenomodulin expression. | 0.1–20 µM of resveratrol | [ | ||
| in vitro, | ROS | Resveratrol’s derivate polydatin protected from advanced glycation as an anti-oxidant property. | 50–500 µg of polydatin | [ | ||
| in vivo, | - | Resveratrol promoted the collagens and the healing process of Achilles tendinopathy, despite diabetic condition. | 10 mg/kg of resveratrol for 14 days | [ |
Figure 4Chemical structures of tendon-supporting phytopharmaceuticals: curcuminoids (A–C), flavones/flavonoids (D–G), green tea extracts (H), and resveratrol (I).